In a report released this week, PriceWaterhouseCoopers predicts that drug sales could double by 2020, due to a wide range of factors, including an aging population, global warming (which could increase infectious diseases) and ever-rising rates of obesity.
The companies that stand the best chance of benefiting from these sales, ironically, aren’t the big pharmaceuticals, who tend to develop “blockbuster” drugs that will reap huge profits–and then make minor improvements to those drugs over time. Instead, it’s companies that repeatedly develop innovative drugs that can prevent or cure diseases that will succeed.
Can big pharma’s way of doing business actually change? Read more about the report in the Reuters article published this week.